{"id":9463,"date":"2026-05-21T16:00:00","date_gmt":"2026-05-21T14:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=34318157e4e261741802ce98f7e6ab78"},"modified":"2026-05-21T16:00:00","modified_gmt":"2026-05-21T14:00:00","slug":"definium-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=9463","title":{"rendered":"Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference"},"content":{"rendered":"

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company\u2019s management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 3:10 p.m. EDT.<\/p><\/a><\/a>

\nAudio webcasts and replays of available presentations will be accessible on Definium\u2019s Investor Relations<\/a> website for up to 90 days following each event.<\/p>

\nAbout Definium Therapeutics<\/b><\/p>

\nThe mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today\u2019s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.<\/p>

\nFor more information, visit https:\/\/definiumtx.com\/<\/a> and follow Definium Therapeutics on Instagram<\/a>, LinkedIn<\/a> and X<\/a>.<\/p> Contacts<\/b>

\nInvestor Contact:<\/b>Gitanjali Jain\nVP, Head of Investor Relations\nir@definiumtx.com<\/a><\/p>

\nMedia Contact:<\/b>media@definiumtx.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

NEW YORK–(BUSINESS WIRE)–Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today an…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9463","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/9463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9463"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/9463\/revisions"}],"predecessor-version":[{"id":9464,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/9463\/revisions\/9464"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}